TY  - JOUR
T1  - Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A double-blind randomized clinical trial
AU  - Hajjar I, Hart M, Chen Y, et al
Y1  - 2012/03/12
N1  - 10.1001/archinternmed.2011.1391
JO  - Archives of Internal Medicine
SP  - 442
EP  - 444
VL  - 172
IS  - 5
N2  - 
Approximately 50% of older hypertensive individuals have difficulties in executive function, the cognitive domain that controls complex tasks.1 Hypertensive individuals with executive dysfunction have a high rate of conversion to dementia.2 To our knowledge, to date, no study has investigated therapeutic options for executive dysfunction. Recent evidence suggests that the renin angiotensin system plays a central role in linking hypertension to cognitive function, offering new therapeutic options for cognitive protection.3 In the brain, angiotensin receptor blockers (ARBs) block the type 1 but not the type 2 receptor, whereas angiotensin-converting enzyme inhibitors (ACEIs) decrease activation of both receptors. Activating the type 2 receptor may provide cognitive protection.4 We therefore hypothesized that an ARB-based regimen would be superior to other antihypertensive regimens in cognitive protection, especially executive function, and conducted a 12-month double-blind randomized clinical trial comparing candesartan, lisinopril, and hydrochlorothiazide in hypertensive individuals with early executive dysfunction.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2011.1391
UR  - http://dx.doi.org/10.1001/archinternmed.2011.1391
ER  -